StockData
Precision BioSciences Inc logo

Precision BioSciences Inc (DTIL) shareholders

DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/3058% above fair value
$7.05−0.23 (-3.16%)

Close on Nov 17, 2026Market cap $194.59MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
64.0%
18M of 28M shares
Institutional holders
95
31 new, 13 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
6 buys · 9 sales
Net sold $395.56K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Octagon Capital Advisors LP
Joint filing with Octagon Investments Master Fund LP (9.99%), Ting Jia (9.99%)
2,328,4859.99%13G (passive)Dec 31, 2025
abrdn Inc.
Joint filing with Aberdeen Group plc (8.88%)
2,138,6038.88%13G (passive)Dec 31, 2025
Empery Asset Management, LP
Joint filing with Ryan M. Lane (7.63%)
1,968,8797.63%13G (passive) amendmentMar 31, 2026
Bleichroeder LP
Joint filing with Bleichroeder Holdings LLC (8.21%), Andrew Gundlach (8.21%)
1,900,0008.21%13G (passive) amendmentDec 31, 2025
Ting Jia
Joint filing with Octagon Capital Advisors LP (5.73%), Octagon Investments Master Fund LP (5.73%)
1,651,4975.73%13G (passive) amendmentSep 30, 2026
Weston Nichols
Joint filing with Lynx1 Capital Management LP (5.40%)
1,390,6115.40%13G (passive)Jul 13, 2026
BlackRock, Inc.1,384,2305.01%13G (passive)Sep 30, 2026
Matthew Smith
Joint filing with Readout Capital, LP (9.30%), Readout Capital GP, LLC (9.30%) and 2 more
1,119,3119.40%13G (passive) amendmentJun 30, 2025
Marc Schneidman
Joint filing with Aquilo Capital Management, LLC (9.90%), Aquilo Capital, L.P. (6.60%)
791,8629.90%13G (passive) amendmentDec 31, 2024
Joseph Edelman
Joint filing with Perceptive Advisors LLC (5.90%), Perceptive Life Sciences Master Fund, Ltd. (5.90%)
426,2935.90%13G (passive) amendmentSep 30, 2024
Novartis Pharma AG
Joint filing with Novartis AG (5.40%)
413,5815.40%13G (passive) amendmentDec 31, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of DTILValueChange% of portfolio
abrdn plc2,230,1788.08%$17.53M–0.02%
Bleichroeder LP2,018,1907.31%$15.86M+355,6902.84%
Octagon Capital Advisors LP1,350,0004.89%$10.61M−886,7320.95%
Boothbay Fund Management, LLC1,346,0044.88%$10.58M+279,9540.14%
BlackRock, Inc.1,172,8734.25%$9.22M+973,1120.00%
Vanguard Capital Management LLC1,116,2414.04%$8.77M+205,5010.00%
Lynx1 Capital Management LP950,4663.44%$7.47M−34,6470.86%
Driehaus Capital Management LLC946,7073.43%$7.44M−48,6640.04%
Empery Asset Management, LP776,0932.81%$6.10M−1,192,7867.05%
Affinity Asset Advisors, LLC646,5762.34%$5.08M+48,6300.23%
Geode Capital Management, LLC620,9812.25%$4.88M+333,8910.00%
Mackenzie Financial Corp480,9971.74%$3.78MNew0.00%
State Street Corp427,3251.55%$3.36M+354,3830.00%
Acadian Asset Management LLC305,7591.11%$2.40M+260,9910.00%
ArrowMark Colorado Holdings LLC274,1400.99%$2.15M+95,0000.09%
Corient Private Wealth LLC245,0580.89%$1.93M+101,2060.00%
Two Sigma Investments, LP237,8630.86%$1.87M−69,9270.00%
Northern Trust Corp190,1880.69%$1.49M+114,1190.00%
JPMorgan Chase & Co180,4520.65%$1.43M+180,4440.00%
Vanguard Fiduciary Trust Co166,5380.60%$1.31M+10,9120.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20269518M64.0%31 / 3114 / 135M3M
Q1 20267816M58.5%21 / 2413 / 114M2M
Q4 20256915M54.7%21 / 228 / 811M1M
Q3 2025565M16.8%11 / 1510 / 71M0M
Q2 2025524M16.2%11 / 148 / 72M1M
Q1 2025484M13.7%6 / 911 / 121M1M
Q4 2024554M14.1%14 / 189 / 102M1M
Q3 2024513M12.0%8 / 109 / 30M0M
Q2 2024473M11.5%8 / 1014 / 40M0M
Q1 2024433M11.6%43 / 00 / 03M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

61 funds held DTIL in Q2 2026, 66% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of DTILValue% of fundAs of
Vanguard Total Stock Market Index Fund778,1392.82%$6.12M0.00%Jun 30, 2026
iShares Russell 2000 ETF427,1671.55%$3.36M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund312,3681.13%$2.46M0.00%Jun 30, 2026
Meridian Contrarian Fund274,1400.99%$2.15M0.32%Jun 30, 2026
Fidelity Small Cap Index Fund261,8450.95%$1.83M0.01%Jul 31, 2026
iShares Russell 2000 Value ETF168,2080.61%$1.32M0.01%Jun 30, 2026
Fidelity Extended Market Index Fund126,6840.46%$882.99K0.00%May 31, 2026
iShares Micro-Cap ETF75,8000.27%$595.79K0.04%Jun 30, 2026
JPMorgan U.S. Small Company Fund61,0760.22%$480.06K0.04%Jun 30, 2026
Schwab Small-Cap Index Fund58,3270.21%$407.71K0.01%Jul 31, 2026
Jacob Discovery Fund52,0890.19%$363.06K2.26%May 31, 2026
Fidelity Total Market Index Fund48,5620.18%$338.48K0.00%May 31, 2026
Fidelity Series Total Market Index Fund37,4960.14%$261.35K0.00%May 31, 2026
Master Small Cap Index Series34,1750.12%$268.62K0.00%Jun 30, 2026
Fidelity Small Cap Value Index Fund33,5660.12%$263.83K0.01%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Michael AmorosoPresident and CEO, Director243,3920.88%Jun 3, 2026
Dario ScimecaChief Legal Officer56,7820.21%Nov 12, 2026
Naresh Haresh TannaChief Financial Officer25,5750.09%Aug 3, 2026
Cassandra Louise GorsuchChief Scientific Officer16,0280.06%Aug 3, 2026
Mei Zhang Lu BurrisChielf Accounting Officer5,1150.02%Aug 3, 2026
John Alexander KellyChief Financial Officer125,8830.46%Jun 3, 2026
J. Jefferson SmithChief Research Officer129,8570.47%Jun 3, 2026
Stanley FrankelDirector41,4780.15%Sep 30, 2026
Geno J. GermanoDirector47,4920.17%Sep 29, 2026
Melinda BrownDirector45,4810.16%Sep 29, 2026
Kevin BuehlerDirector49,1370.18%Jun 5, 2026
Shari Lisa PireDirector35,0280.13%Jun 5, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Dario Scimeca
Chief Legal Officer
Nov 10, 2026Sale(10b5-1 plan)−2,821$9.75$27.50K56,782
Stanley Frankel
Director
Sep 28, 2026Buy+1,000$6.00$6.00K41,478
Geno J. Germano
Director
Sep 25, 2026Buy+2,609$6.28$16.38K47,492
Melinda Brown
Director
Sep 25, 2026Buy+1,135$6.27$7.12K45,481
Geno J. Germano
Director
May 20, 2026Option exercise+21,000––44,883
Kevin Buehler
Director
May 20, 2026Option exercise+21,000––49,137
Stanley Frankel
Director
May 20, 2026Option exercise+21,000––40,478
Melinda Brown
Director
May 20, 2026Option exercise+21,000––44,346
Shari Lisa Pire
Director
May 20, 2026Option exercise+21,000––35,028
Dario Scimeca
General Counsel and Secretary
Feb 18, 2026Sale(10b5-1 plan)−4,925$3.84$18.91K56,457
J. Jefferson Smith
Chief Research Officer
Feb 18, 2026Sale(10b5-1 plan)−4,925$3.84$18.91K121,926
John Alexander Kelly
Chief Financial Officer
Feb 18, 2026Sale(10b5-1 plan)−8,149$3.84$31.29K125,883
Michael Amoroso
President and CEO, Director
Feb 18, 2026Sale(10b5-1 plan)−20,559$3.84$78.95K243,392
Dario Scimeca
General Counsel and Secretary
Feb 17, 2026Option exercise+16,667––61,382
J. Jefferson Smith
Chief Research Officer
Feb 17, 2026Option exercise+16,667––126,851
John Alexander Kelly
Chief Financial Officer
Feb 17, 2026Option exercise+27,584––134,032
Michael Amoroso
President and CEO, Director
Feb 17, 2026Option exercise+67,797––263,951
Michael Amoroso
President and CEO, Director
Jan 22, 2026Sale(10b5-1 plan)−34,799$4.17$145.11K196,154
John Alexander Kelly
Chief Financial Officer
Jan 21, 2026Sale(10b5-1 plan)−15,213$4.03$61.31K106,448
Dario Scimeca
General Counsel and Secretary
Jan 21, 2026Sale(10b5-1 plan)−8,854$4.03$35.68K44,715
J. Jefferson Smith
Chief Research Officer
Jan 21, 2026Sale(10b5-1 plan)−10,200$4.03$41.11K110,184
J. Jefferson Smith
Chief Research Officer
Jan 21, 2026Option exercise+16,219––120,384
John Alexander Kelly
Chief Financial Officer
Jan 20, 2026Option exercise+3,888––81,186
John Alexander Kelly
Chief Financial Officer
Jan 20, 2026Option exercise+26,575––121,661
John Alexander Kelly
Chief Financial Officer
Jan 20, 2026Option exercise+13,900––95,086
Michael Amoroso
President and CEO, Director
Jan 20, 2026Option exercise+69,421––230,953
Michael Amoroso
President and CEO, Director
Jan 20, 2026Option exercise+8,888––124,463
Michael Amoroso
President and CEO, Director
Jan 20, 2026Option exercise+37,069––161,532
Dario Scimeca
General Counsel and Secretary
Jan 20, 2026Option exercise+14,908––53,569
Dario Scimeca
General Counsel and Secretary
Jan 20, 2026Option exercise+8,425––38,661
Dario Scimeca
General Counsel and Secretary
Jan 20, 2026Option exercise+1,978––30,236
J. Jefferson Smith
Chief Research Officer
Jan 20, 2026Option exercise+2,500––93,718
J. Jefferson Smith
Chief Research Officer
Jan 20, 2026Option exercise+10,447––104,165
Geno J. Germano
Director
Dec 16, 2025Buy+3,000$4.72$14.16K23,883
Stanley Frankel
Director
Dec 16, 2025Buy+2,700$4.70$12.69K19,478
Melinda Brown
Director
Dec 15, 2025Buy+1,381$4.97$6.86K23,346
Dario Scimeca
General Counsel and Secretary
Nov 3, 2025Sale(10b5-1 plan)−665$6.49$4.32K28,258
Michael Amoroso
President and CEO, Director
Nov 3, 2025Sale(10b5-1 plan)−3,409$6.49$22.12K115,575
John Alexander Kelly
Chief Financial Officer
Nov 3, 2025Sale(10b5-1 plan)−1,303$6.49$8.46K77,298
Dario Scimeca
General Counsel and Secretary
Nov 2, 2025Option exercise+1,835––28,923
Michael Amoroso
President and CEO, Director
Nov 2, 2025Option exercise+9,444––118,984
John Alexander Kelly
Chief Financial Officer
Nov 2, 2025Option exercise+3,605––78,601
Stanley Frankel
Director
Sep 26, 2025Buy+2,700$4.97$13.42K16,778
Melinda Brown
Director
Sep 22, 2025Buy+1,400$4.89$6.85K21,965
John Alexander Kelly
Chief Financial Officer
Jul 3, 2025Sale(10b5-1 plan)−14,827$4.26$63.16K73,485
Kevin Buehler
Director
Jun 25, 2025Buy+5,076$4.16$21.12K28,137
Melinda Brown
Director
Jun 25, 2025Buy+1,682$4.14$6.96K20,565
Geno J. Germano
Director
May 27, 2025Option exercise+9,826––20,883
Kevin Buehler
Director
May 27, 2025Option exercise+9,826––23,061
Melinda Brown
Director
May 27, 2025Option exercise+9,826––18,883
Shari Lisa Pire
Director
May 27, 2025Option exercise+9,826––14,028
Stanley Frankel
Director
May 27, 2025Option exercise+9,826––14,078
Melinda Brown
Director
Mar 26, 2025Buy+1,839$4.75$8.74K9,057
Kevin Buehler
Director
Mar 26, 2025Buy+4,523$4.67$21.12K13,235
Geno J. Germano
Director
Mar 25, 2025Buy+3,250$5.30$17.23K11,057
Michael Amoroso
President and CEO, Director
Mar 24, 2025Sale(10b5-1 plan)−964$5.56$5.36K109,540
Michael Amoroso
President and CEO, Director
Mar 21, 2025Option exercise+3,417––110,504
J. Jefferson Smith
Chief Research Officer
Mar 4, 2025Sale(10b5-1 plan)−154$4.91$75687,805
Dario Scimeca
General Counsel and Secretary
Mar 4, 2025Sale(10b5-1 plan)−272$4.91$1.34K25,000
John Alexander Kelly
Chief Financial Officer
Mar 3, 2025Option exercise+1,702––86,256

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
7.83%
2M shares short
Days to cover
10.5
At 0M shares a day
Change since last report
-11.0%
From 2M shares
Short volume, 20 days
53.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Precision BioSciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 32,729 shares on Sep 23, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Dario Scimeca
Officer
Nov 10, 20262,821$27.52KNov 10, 2026ESPP Purchase
J. Jefferson Smith
Officer
Nov 6, 2026875$8.96KNov 6, 2026Founders Shares
J. Jefferson Smith
Officer
Nov 5, 20267,056$72.41KNov 5, 2026Founder Shares
J. Jefferson Smith
Officer
Feb 18, 20264,925$18.93KFeb 18, 2026Restricted Stock Vesting
Michael Amoroso
Officer, Director
Feb 18, 202620,559$79.02KFeb 18, 2026Restricted Stock Vesting
Dario Scimeca
Officer
Feb 18, 20264,925$18.93KFeb 18, 2026Restricted Stock Vesting
John Alexander Kelly
Officer
Feb 18, 20268,149$31.32KFeb 18, 2026Restricted Stock Vesting
Michael Amoroso
Officer, Director
Jan 22, 202634,799$145.20KJan 22, 2026Restricted Stock Vesting
Dario Scimeca
Officer
Jan 21, 20268,854$35.65KJan 21, 2026Restricted Stock Vesting
J. Jefferson Smith
Officer
Jan 21, 202610,200$41.07KJan 21, 2026Restricted Stock Vesting
John Alexander Kelly
Officer
Jan 21, 202615,213$61.26KJan 21, 2026Restricted Stock Vesting
John Alexander Kelly
Officer
Nov 3, 20251,303$8.46KNov 3, 2025Restricted Stock Vesting
Michael Amoroso
Officer, Director
Nov 3, 20253,409$22.12KNov 3, 2025Restricted Stock Vesting
Dario Scimeca
Officer
Nov 3, 2025665$4.32KNov 3, 2025Restricted Stock Vesting
John Alexander Kelly
Officer
Jul 3, 202514,827$63.21KJul 3, 2025Restricted Stock Vesting

See a number that looks wrong?